相关实验视频

Updated: Jun 6, 2025

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

大麻合法化对带组织四大麻素水平的影响

Kimberly Spence^1,2, Sarah Milota^1,2, Paula Buchanan²

¹Division of Neonatal-Perinatal Medicine, SSM Cardinal Glennon Children's Hospital, Saint Louis, Missouri.

American journal of perinatology

|November 21, 2024

概括

伊利诺伊州大麻合法化导致胎儿对四大麻 (THC) 的暴露增加. 带组织分析显示,合法化后THC的比率和度更高,表明产前大麻暴露程度更高.

科学领域:

围产儿医学围产儿医学
药理学药理学是指药理学的学科.
公共卫生公共卫生

背景情况:

大麻合法化在全球范围内不断扩大,引发了对对孕产妇和胎儿健康的潜在影响的担忧.
评估胎儿对四大麻 (THC) 的暴露对于理解这些影响至关重要.
带组织作为一个有价值的生物矩阵来评估产前暴露.

研究的目的:

评估大麻合法化对二 (THC) 在带组织中的水平的影响.
为了确定THC阳性率和度在伊利诺伊州娱乐大麻合法化后是否发生变化.
为了利用带组织THC分析作为胎儿大麻暴露的代理.

主要方法:

使用了回顾性,观察性研究设计.
在伊利诺伊州大麻合法化之前 (2018年10月至2019年6月) 和之后 (2019年7月至2021年8月) 分析了带组织样本的THC度.
统计分析比较了合法化前和合法化后期间的THC阳性率和平均度.

主要成果:

在合法化前总共分析了811条带,在合法化后分析了2,170条带.
测试THC阳性的带组织的百分比在合法化后显著增加 (46.2%对40.6%,p <0.01).
在合法化后,带组织中THC的平均度增加了51% (6.2 ng/g与4.1 ng/g相比,p < 0.001).

结论:

伊利诺伊州的娱乐大麻合法化与胎儿接触THC的增加有关.
带组织THC阳性和度作为产前大麻暴露的可靠指标.
这些发现突出了关于合法化后孕前大麻暴露率上升的公共卫生问题.

更多相关视频

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...